Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
What is the ticker symbol for Aldeyra Therapeutics Inc? What does ALDX stand for in stocks?
ALDX is the stock ticker symbol of Aldeyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Aldeyra Therapeutics Inc (ALDX)?
As of Thu Nov 07 2024, market cap of Aldeyra Therapeutics Inc is 317.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ALDX stock?
You can check ALDX's fair value in chart for subscribers.
Is Aldeyra Therapeutics Inc a good stock to buy?
The fair value guage provides a quick view whether ALDX is over valued or under valued. Whether Aldeyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aldeyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALDX.
What is 5 year return on Aldeyra Therapeutics Inc's stock?
In the past 10 years, Aldeyra Therapeutics Inc has provided -0.039 (multiply by 100 for percentage) rate of return.